INDICATIONS

• Reversal of narcotic toxicity causing respiratory depression, hypertension, perfusion failure

PRECAUTIONS

• Provide augmented ventilation prior to administration to avoid sympathetic stimulation
• Administering to addicted infants may cause seizures or withdrawal symptoms
• Sudden reversal of narcotic effects. Consider use of non-opioid agents for pain management
• Half-life of naloxone is typically shorter than the narcotic. May require multiple doses, or using a continuous-infusion
• May be given IV/IO/IM

DOSAGE & ADMINISTRATION

• Sub-Q: 0.1 mg/kg every 2 minutes PRN
• In patients where total reversal is not required, 0.001–0.005 mg/kg (1–5 mcg/kg) may be titrated
• Intra-nasal: 4–8 mg (1 nasal administration unit)
• Can be repeated PRN using alternating nostrils q 2–3 minutes
• Can be titrated by continuous infusion: 0.002–0.16 mg/kg (2–160 mcg/kg) per hour
• Can be given IV/IO/IM/sub-Q. Although endotracheal administration is acceptable, the other routes are preferred according to the 2025 Guidelines